Evidence map›Paper›PMID 40625591›Full record

ReviewThe breast journal2025

Underserved Patient Populations With Metastatic Breast Cancer: A Review of Progress and Remaining Challenges.

Fatima Cardoso, Rachel Wuerstlein, Tomoyuki Aruga, Renate Haidinger, Matteo Lambertini, Christine Benjamin, Elisenda Llabrés Valentí, Carmen Criscitiello, Matti Aapro, Generosa Grana and 2 more

Abstract readReview
In one paragraph

Review in The breast journal, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Fatima CardosoAdvanced Breast Cancer Global Alliance, Lisbon, Portugal.ORCID 0000-0002-6692-2249
Rachel WuerstleinDepartment of Obstetrics and Gynecology, Ludwig Maximilian University, Munich, Germany.ORCID 0000-0001-7268-0840
Tomoyuki ArugaDepartment of Surgery, Institute of Science Tokyo, Tokyo, Japan.ORCID 0000-0003-3442-8972
Renate HaidingerAdvanced Breast Cancer Global Alliance, Lisbon, Portugal.ORCID 0000-0002-8567-7314
Matteo LambertiniDepartment of Internal Medicine and Medical Specialties, University of Genoa, Genoa, Italy.ORCID 0000-0003-1797-5296
Christine BenjaminSHARE Cancer Support, New York, New York, USA.ORCID 0000-0001-8382-0781
Elisenda Llabrés ValentíDepartment of Medical Oncology, Insular University Hospital of Gran Canaria, Las Palmas de Gran Canaria, Spain.ORCID 0000-0002-3168-8974
Carmen CriscitielloDepartment of Oncology and Hematology, University of Milan, Milan, Italy.ORCID 0000-0001-9064-0113
Matti AaproDepartment of Medical Oncology, Genolier Cancer Center, Genolier, Switzerland.ORCID 0000-0003-3570-8319
Generosa GranaMD Anderson Cancer Center at Cooper, Cooper University Health Care, Camden, New Jersey, USA.ORCID 0000-0002-3528-9516
Sharon S GentryAcademy of Oncology Nurse & Patient Navigators, Cranbury, New Jersey, USA.ORCID 0000-0001-9142-0681
Eduard VrdoljakDepartment of Oncology, University of Split, Split, Croatia.ORCID 0000-0002-2908-3474

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Breast cancer presents a significant risk to public health and is the primary cause of cancer-related death in women. Awareness of metastatic breast cancer (mBC) continues to increase, and advances have been made; however, challenges remain for many patient populations that do not receive equal opportunities along the treatment pathway. The Underserved Patient Population (UPP) Coalition Task Force, a group of international experts in mBC, held meetings between 2022 and 2023 to prioritise the needs of UPPs and propose solutions. The key unmet needs identified included the following: delayed diagnosis of mBC due to difficulties in the presentation of patients to the healthcare system and a lack of primary care physician and non-breast cancer specialist understanding of the signs and symptoms of mBC; difficulty navigating the mBC patient pathway due to suboptimal use of multidisciplinary care and limited communication between HCPs; unequal access to the most appropriate mBC treatment options and supportive therapy due to the unconscious bias of HCPs, and direct and indirect financial toxicity for patients; and negative impact on QoL resulting from the limited uptake of shared decision-making, low prioritisation of patient preferences and a lack of personalised care. This paper aims to shine light on initiatives supporting underserved patients with mBC, illustrate the remaining gaps in care and call upon the global community to change how care is delivered to UPPs.

Indexed as

Breast NeoplasmsVulnerable PopulationsFemaleHealth Services AccessibilityHumansNeoplasm Metastasisadvanced breast cancerhealth disparitieshealth inequitymetastatic breast cancerunmet needs

Identifiers

PMID40625591
PMCPMC12234164

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.